The Novartis Commitment to Patients and Caregivers

Only by working together and delivering on the four pillars of our Commitment, can we improve outcomes for patients and change the practice of medicine.

<table>
<thead>
<tr>
<th>PATIENT ORGANIZATIONS representing</th>
<th>PATIENTS contributed to its development</th>
<th>NOVARTIS ASSOCIATES(^1) own it as an aspiration to embed the perspective of patients and caregivers systematically in our decision-making</th>
</tr>
</thead>
<tbody>
<tr>
<td>40+</td>
<td>200m</td>
<td>108,000</td>
</tr>
</tbody>
</table>

Our Commitment is based on four pillars

- Respecting and understanding the patient community perspective
- Conducting responsible clinical trials
- Expanding access to our medicines
- Recognizing the importance of transparency and reporting

Sharing two years of progress

70%

- **EARLY RESEARCH PROGRAMS**\(^2\) in general medicines obtained patient insights before first in human trials (healthy volunteers). Piloted patient panels for five Proof of Concept indications

18

- **CLINICAL DEVELOPMENT PROGRAMS**\(^2\) comprising 34 clinical trials, had a patient engagement component to obtain the patient perspective on the design and/or conduct of clinical trials

55

- **CLINICAL TRIALS** included Patient Reported Outcomes (PRO) conducted in 68 countries

10,503

- **PATIENTS REACHED THROUGH MANAGED ACCESS PROGRAMS**\(^4\) 96.8% requests approved for 34 compounds in 74 countries - providing pre-approval access to Novartis medicines, 81% increase vs. 2018

50

- **SIMPLIFIED SUMMARIES**\(^3\) from Phase 1 - 4 clinical trials sent to investigators to share with 8,016 trial participants and posted on novartisclinicaltrials.com

16m

- **PATIENTS**\(^5\) reached through Access programs

---

\(^1\) 2019 data
\(^2\) Patient engagement component defined as interaction with patients to seek input, advice or guidance
\(^3\) https://www.novartis.com/ClinicalTrials/Terms
\(^4\) https://www.novartis.com/our-focus/healthcare-professionals/managed-access-programs

G-PA-PO-202002/1
Our Commitment to Patients and Caregivers

2019 facts and figures

Respecting and understanding the patient community perspective

Connecting 400 patient advocates in 18 country hubs across Europe with digitally enabled technology, with the European Patient Innovation Summit (EPIS)\(^1\)

120 patient organizations in 20 disease areas from 28 countries engaged in global initiatives to inform decision-making\(^1\)

27 capability and capacity building programs of patient organizations supported\(^1\)

10 co-created initiatives between patient organizations and Novartis for disease education, awareness and research collaborations\(^1\)

# 4 ranking in Corporate Reputation – evaluated by 1500 patient organizations\(^2\)

# 1 reputation ranking in Skin disease\(^2\)

# 2 reputation ranking in Cancer, Autoimmune disease, Neurological disorders and Multiple Sclerosis\(^2\)

Conducting responsible clinical trials

103 patients participated in three studies to inform decisions on the type of devices, technology or services to be developed for use in clinical studies

Trial feedback questionnaires from 20 clinical trials sent to patients to obtain insights on their participation experience; 750 patient responses received in 24 countries

138 clinical trials listed for secure, voluntary data sharing on ClinicalStudyDataRequest.com CSDR\(^3\)

3 clinical trials set up to pilot return of individual results to trial participants (IRR) once the clinical trial report is publicly available

Expanding access to our medicines\(^4\)

#2 in Access to Medicines Index – assessing companies' performance in providing access to medicines for patients

300 000+ patients reached in 50+ lower income countries with 90+ local brands

2.1m patients reached through Novartis Access offering a portfolio of 15 patented and off-patent medicines addressing non-communicable diseases (NCDs) in lower income countries

10m people reached through training and health education programs

Recognizing the importance of transparency and reporting

2745 clinical trials posted on novartisclinicaltrials.com, sharing results of clinical trials with society

Returning to society with 12 manuscripts and 13 posters/abstracts published on insights obtained from the patient community, to share the learnings

Reported engagement with and support for 1448 patient organizations in 71 countries in Transfer of Value report\(^5\)

---

\(^1\) Refers to global and regional initiatives/activities only

\(^2\) The Corporate Reputation of Pharma in 2018, published April 2019

\(^3\) https://www.clinicalstudydatarequest.com/
